Diakine Platform (Inflammatory)

About Deka Biosciences

Deka Biosciences is an early-stage biotech pioneering a targeted cytokine therapy platform named Diakine™. The platform engineers single-chain fusion proteins that pair either two anti-inflammatory cytokines (for autoimmune/inflammatory diseases) or a stimulatory cytokine with an anti-inflammatory cytokine (for cancer) with a tissue-targeting scFv antibody fragment. This approach seeks to overcome the systemic toxicity and limited efficacy of traditional cytokine therapies by localizing potent immune modulation to the site of disease. The company is advancing a preclinical pipeline focused on major indications like Crohn's disease, psoriasis, rheumatoid arthritis, sepsis, and solid tumors.

Therapeutic Areas